Relative Bioavailability of 10 mg BI 11634 Immediate Release Tablet (IR) Compared to 10 mg of Oral Solution Following Oral Administration in Healthy Male Volunteers (Open-label, Single-dose, Intra-individual Comparison); Determination of Pharmacokinetics of 5 mg, 10 mg and 25 mg IR-tablet Formulation (Open-label, Single Dose)

Trial Profile

Relative Bioavailability of 10 mg BI 11634 Immediate Release Tablet (IR) Compared to 10 mg of Oral Solution Following Oral Administration in Healthy Male Volunteers (Open-label, Single-dose, Intra-individual Comparison); Determination of Pharmacokinetics of 5 mg, 10 mg and 25 mg IR-tablet Formulation (Open-label, Single Dose)

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2014

At a glance

  • Drugs BI 11634 (Primary) ; BI 11634 (Primary)
  • Indications Vascular disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 21 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top